Drugs / UBX0101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04229225 | Jan → Sep 2020 | osteoarthritis, knee | Unity Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03513016 | May 2018 → Mar 2019 | osteoarthritis, knee | Unity Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04129944 | Oct 2019 → May 2020 | osteoarthritis, knee | Unity Biotechnology, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UBX0101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04129944 ↗ |
| Route | Other | “single-dose intra-articular administration of UBX0101” NCT04129944 ↗ |